治疗COVID-19嗅觉功能障碍的嗅觉训练,棕乙胺与黄素,或联合治疗:一个盲控多中心随机试验
Arianna Di Stadio1, Salvatore Gallina2, Salvatore Cocuzza3
1Otolaryngology Unit, GF Ingrassia Department, University of Catania, Catania, Italy. ariannadistadio@hotmail.com.
概括
嗅觉训练和联合超微克隆的棕甲基乙醇胺与黄素 (um-PEA-LUT) 的联合治疗显著改善了COVID-19后的慢性嗅觉功能障碍. 这种方法在长期恢复气味损失方面,与单个治疗方法相比,显示出更高的疗效.
科学领域:
- 神经学 神经学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性嗅觉功能障碍是COVID-19感染后的一个常见的,使人衰弱的症状.
- 有限的基于证据的疗法存在于COVID-19后持续的嗅觉丧失.
- 神经炎症与COVID-19相关的嗅觉功能障碍的病理生理学有关.
研究的目的:
- 为了评估单独的嗅觉训练 (OT) 的疗效,单独使用co-ultramicronized palmitoylethanolamide和luteolin (um-PEA-LUT),或用于COVID-19后慢性嗅觉功能障碍的联合治疗.
- 为了比较不同治疗臂的嗅觉功能的恢复率.
- 评估干预措施的安全性和耐受性.
主要方法:
- 一个双盲,安慰剂控制,多中心随机临床试验,涉及202名嗅觉功能障碍患者,持续超过COVID-19后6个月.
- 患者被随机分为四组:OT +安慰剂,um-PEA-LUT (每天一次) 单独,um-PEA-LUT (每天两次) 单独,或组合OT + um-PEA-LUT (每天一次).
- 嗅觉功能在基线和1,2,3个月时使用Sniffin' Sticks气味识别测试进行评估. 主要结局是气味识别得分的改善>3分.
主要成果:
- 组合治疗组在90天 (89.2%) 的恢复率显著提高 (>3点改善的气味识别),与安慰剂 (36.8%) 的嗅觉训练相比,每天两次单独使用um-PEA-LUT (40%) 和每天一次单独使用um-PEA-LUT (41.6%) (p < 0.00001).
- 接受um-PEA-LUT单独治疗的患者显示,亚临床改善的发生率 (<3点改善) 比安慰剂组的嗅觉训练高 (p < 0.0001).
- 在任何治疗组中都没有报告任何不良事件,这表明了有利的安全性.
结论:
- 嗅觉训练和每天一次的um-PEA-LUT的联合治疗在恢复长期COVID-19后嗅觉丧失的患者的嗅觉功能方面显著更有效.
- 组合疗法为慢性嗅觉功能障碍提供了一个有希望的基于证据的治疗选择.
- Um-PEA-LUT是一种抗神经炎症补充剂,可能在缓解与病毒后嗅觉损失相关的神经炎症方面发挥作用.
关键词:
无症 (Anosmia) 是一种无症.在 COVID-19 疫情中,临床试验临床试验是指临床试验的临床试验.新冠病毒新冠病毒新冠病毒.缺血症是什么意思 缺血症是什么意思卢特奥林是什么? 卢特奥林是什么?神经炎症是一种神经炎症.嗅觉培训 嗅觉培训 嗅觉培训在PEA中,PEA是PEA.在PEALUTUT中.棕甲基乙醇胺的使用方法在COVID-19的后急性后果.随机试验是指随机的试验.这就是SARS-CoV-2病毒.嗅觉障碍 嗅觉障碍 嗅觉障碍更多相关视频
04:00Author Spotlight: Assessing the Olfactory Effects of Airborne Pollutants — Buried Food and Social Odor Tests
Published on: September 13, 2024
879
06:13Author Spotlight: Exploring Olfactory Influences on Corticospinal Excitability - Insights and Innovations in Neurological Research
Published on: January 19, 2024
1.1K
相关概念视频
Olfactory Receptors: Location and Structure
9.4K
The process of olfaction, also known as the sense of smell, is a sophisticated chemical response system. The specialized sensory neurons that facilitate this process, known as olfactory receptor neurons, are situated in an upper segment of the nasal cavity, known as the olfactory epithelium. Olfactory sensory neurons are bipolar, with their dendrites extending from the epithelium's apex into the mucus that lines the nasal cavity. Airborne molecules, when inhaled, traverse the olfactory...
9.4K
Olfaction
44.5K
The sense of smell is achieved through the activities of the olfactory system. It starts when an airborne odorant enters the nasal cavity and reaches olfactory epithelium (OE). The OE is protected by a thin layer of mucus, which also serves the purpose of dissolving more complex compounds into simpler chemical odorants. The size of the OE and the density of sensory neurons varies among species; in humans, the OE is only about 9-10 cm2.
The olfactory receptors are embedded in the cilia of the...
The olfactory receptors are embedded in the cilia of the...
44.5K
Physiology of Smell and Olfactory Pathway
8.8K
Humans detect odors with the help of specialized cells located in the upper part of the nasal cavity, called olfactory receptor neurons (ORNs). ORNs possess hair-like structures called cilia, which are receptive to sensations from the inhaled air. When an odorant molecule binds to a specific receptor on the cell of the cilia, it leads to a series of events that ultimately cause the ORN to send electrical signals to the olfactory bulb in the brain through the olfactory nerves.
The olfactory...
The olfactory...
8.8K
Alzheimer's Disease: Treatment
222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222
